Pages that link to "Q44186929"
Jump to navigation
Jump to search
The following pages link to Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study (Q44186929):
Displaying 50 items.
- Carbapenem-Resistant Enterobacteriaceae: A Strategic Roadmap for Infection Control (Q30148824) (← links)
- Multidrug resistant Acinetobacter (Q33711902) (← links)
- Resistance to Colistin in Klebsiella Pneumoniae: A 4.0 Strain? (Q33803459) (← links)
- Colistin in the 21st century (Q33847509) (← links)
- Pharmacology of polymyxins: new insights into an 'old' class of antibiotics (Q34346283) (← links)
- Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes (Q34552966) (← links)
- Multidrug-resistant Gram-negative infections: what are the treatment options? (Q35002302) (← links)
- Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-β-lactamase (Q35019811) (← links)
- Pseudomonas Aeruginosa: Resistance to the Max (Q35084559) (← links)
- ESBLs: A Clear and Present Danger? (Q35101453) (← links)
- The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A. (Q35139454) (← links)
- Trends in nosocomial bloodstream infections in a burn intensive care unit: an eight-year survey (Q35280740) (← links)
- Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula (Q35364351) (← links)
- Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model (Q35598403) (← links)
- Impact of two-component regulatory systems PhoP-PhoQ and PmrA-PmrB on colistin pharmacodynamics in Pseudomonas aeruginosa (Q36018883) (← links)
- Interaction of colistin and colistin methanesulfonate with liposomes: colloidal aspects and implications for formulation. (Q36222127) (← links)
- Emergence of OXA-48 and OXA-181 carbapenemases among Enterobacteriaceae in South Africa and evidence of in vivo selection of colistin resistance as a consequence of selective decontamination of the gastrointestinal tract (Q36506349) (← links)
- Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports (Q36556499) (← links)
- Access to antibiotics: a safety and equity challenge for the next decade (Q36689032) (← links)
- Epidemiological interpretation of studies examining the effect of antibiotic usage on resistance (Q36757737) (← links)
- A 5-year Surveillance Study on Antimicrobial Resistance of Acinetobacter baumannii Clinical Isolates from a Tertiary Greek Hospital (Q37306655) (← links)
- Current control and treatment of multidrug-resistant Acinetobacter baumannii infections (Q37330689) (← links)
- Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system (Q37333088) (← links)
- Inhaled colistin for treatment of pneumonia due to colistin-only-susceptible Acinetobacter baumannii. (Q37418760) (← links)
- Current treatment of pseudomonal infections in the elderly. (Q37529775) (← links)
- Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria (Q37544860) (← links)
- New information about the polymyxin/colistin class of antibiotics (Q37636150) (← links)
- Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii (Q37728145) (← links)
- Multidrug-resistant Gram-negative infections: the use of colistin. (Q37785545) (← links)
- Multidrug-resistant Gram-negative bacteria: how to treat and for how long (Q37815675) (← links)
- Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes (Q37894694) (← links)
- When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock (Q37907967) (← links)
- Ertapenem use and antimicrobial resistance to group 2 carbapenems in Gram-negative infections: a systematic review (Q38083315) (← links)
- Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence (Q38147851) (← links)
- Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens (Q38262205) (← links)
- Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial (Q38394222) (← links)
- Optimum treatment strategies for carbapenem-resistant Acinetobacter baumannii bacteremia (Q38416932) (← links)
- Risk factors for infection with colistin-resistant gram-negative microorganisms: a multicenter study. (Q39728483) (← links)
- In Vitro Assessment of Combined Polymyxin B and Minocycline Therapy against Klebsiella pneumoniae Carbapenemase (KPC)-Producing K. pneumoniae (Q40239359) (← links)
- In Vitro Synergistic Effects of Antimicrobial Combinations on Extensively Drug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Isolates. (Q40855475) (← links)
- Induction and nosocomial dissemination of carbapenem and polymyxin-resistant Klebsiella pneumoniae. (Q41129054) (← links)
- Colistin Resistance in Carbapenem-Resistant Klebsiella pneumoniae: De Novo or Drug Exposure? (Q41987700) (← links)
- Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. (Q42215035) (← links)
- First documented outbreak of KPC-2-producing Klebsiella pneumoniae in Switzerland: infection control measures and clinical management (Q42230561) (← links)
- Detection, treatment, and prevention of carbapenemase-producing Enterobacteriaceae: recommendations from an International Working Group. (Q42258248) (← links)
- In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group (Q42575942) (← links)
- Reply to "selective digestive tract decontamination and spread of colistin resistance: antibiotic prophylaxis is not a substitute for hygiene". (Q42706798) (← links)
- Effectiveness and safety of colistin: prospective comparative cohort study (Q43124623) (← links)
- Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection (Q43127814) (← links)
- Editorial commentary: Polymyxin-resistant Acinetobacter baumannii: urgent action needed (Q43226964) (← links)